Conditions: Hepatitis C Virus
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 71
Healthy volunteers: no

Brief summary:
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3

Detailed description:

Arms:
arm 1: Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks

Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks

Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks arm 2: Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks

Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks

Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks

Interventions: intervention 1: Pegylated-Interferon-lambda intervention 2: Ribavirin intervention 3: Daclatasvir
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: